{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T14:36:43Z","timestamp":1782830203629,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,3,29]],"date-time":"2014-03-29T00:00:00Z","timestamp":1396051200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s40263-014-0159-1","type":"journal-article","created":{"date-parts":[[2014,3,28]],"date-time":"2014-03-28T18:24:23Z","timestamp":1396031063000},"page":"483-490","source":"Crossref","is-referenced-by-count":10,"title":["A Cross-Sectional Study on Drug Use in Multiple System Atrophy"],"prefix":"10.1007","volume":"28","author":[{"given":"Mar\u00eda Ver\u00f3nica","family":"Rey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Perez-Lloret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Pavy-Le Traon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassilios G.","family":"Meissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Tison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,29]]},"reference":[{"key":"159_CR1","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S1474-4422(09)70288-1","volume":"8","author":"N Stefanova","year":"2009","unstructured":"Stefanova N, Bucke P, Duerr S, et al. Multiple system atrophy: an update. Lancet Neurol. 2009;8:1172\u20138.","journal-title":"Lancet Neurol"},{"issue":"Suppl 12","key":"159_CR2","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1002\/mds.20543","volume":"20","author":"GK Wenning","year":"2005","unstructured":"Wenning GK, Geser F, Poewe W. Therapeutic strategies in multiple system atrophy. Mov Disord. 2005;20(Suppl 12):S67\u201376.","journal-title":"Mov Disord"},{"key":"159_CR3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/0470842555.ch29","volume-title":"Pharmacoepidemiology","author":"D Lee","year":"2000","unstructured":"Lee D, Bergman U. Studies of drug utilization. In: Strom BL, editor. Pharmacoepidemiology. Chichester: Wiley; 2000. p. 463\u201382."},{"key":"159_CR4","unstructured":"Centre de r\u00e9f\u00e9rence de l\u2019atrophie multysist\u00e9matis\u00e9e. http:\/\/www.chu-toulouse.fr\/-centre-de-reference-de-l-atrophie-multisyst\u00e9matis\u00e9e (Accessed 2013 Oct. 15)."},{"key":"159_CR5","unstructured":"Les Maladies Rares. http:\/\/www.sante.gouv.fr\/les-maladies-rares.html (Accessed 2013 Oct. 15)."},{"key":"159_CR6","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/mds.20255","volume":"19","author":"GK Wenning","year":"2004","unstructured":"Wenning GK, Tison F, Seppi K, et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord. 2004;19:1391\u2013402.","journal-title":"Mov Disord"},{"key":"159_CR7","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.parkreldis.2011.12.009","volume":"18","author":"N Damon-Perriere","year":"2012","unstructured":"Damon-Perriere N, Foubert-Samier A, De Cock VC, et al. Assessment of the SCOPA-Aut questionnaire in multiple system atrophy: relation to UMSARS scores and progression over time. Parkinsonism Relat Disord. 2012;18:612\u20135.","journal-title":"Parkinsonism Relat Disord"},{"key":"159_CR8","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/mds.23742","volume":"26","author":"TA Pavy-Le","year":"2011","unstructured":"Pavy-Le TA, Amarenco G, Duerr S, et al. The movement disorders task force review of dysautonomia rating scales in Parkinson\u2019s disease with regard to symptoms of orthostatic hypotension. Mov Disord. 2011;26:1985\u201392.","journal-title":"Mov Disord"},{"key":"159_CR9","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","volume":"71","author":"S Gilman","year":"2008","unstructured":"Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71:670\u20136.","journal-title":"Neurology"},{"key":"159_CR10","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s00228-011-1198-x","volume":"68","author":"S Perez-Lloret","year":"2012","unstructured":"Perez-Lloret S, Rey MV, Fabre N, et al. Do Parkinson\u2019s disease patients disclose their adverse events spontaneously? Eur J Clin Pharmacol. 2012;68:857\u201365.","journal-title":"Eur J Clin Pharmacol"},{"key":"159_CR11","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1212\/WNL.42.6.1142","volume":"42","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Ben-Shlomo Y, Daniel SE, et al. What features improve the accuracy of clinical diagnosis in Parkinson\u2019s disease: a clinicopathologic study. Neurology. 1992;42:1142\u20136.","journal-title":"Neurology"},{"key":"159_CR12","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2012, Oslo 2011."},{"key":"159_CR13","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov Disord. 2010;25:2649\u201353.","journal-title":"Mov Disord"},{"key":"159_CR14","first-page":"153","volume-title":"Recent developments in Parkinson\u2019s disease","author":"S Fahn","year":"1987","unstructured":"Fahn S, Elton RL, Members of the UPDRS committee. Unified Parkinson\u2019s Disease Rating Scale. In: Fahn S, Mardsen CD, Goldstein M, editors. Recent developments in Parkinson\u2019s disease. New York: McMillan; 1987. p. 153\u201363."},{"key":"159_CR15","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/j.1440-1681.1998.tb02179.x","volume":"25","author":"J Ludbrook","year":"1998","unstructured":"Ludbrook J. Multiple comparison procedures updated. Clin Exp Pharmacol Physiol. 1998;25:1032\u20137.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"159_CR16","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1002\/mds.23192","volume":"25","author":"M Kollensperger","year":"2010","unstructured":"Kollensperger M, Geser F, Ndayisaba JP, et al. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European Multiple System Atrophy Registry. Mov Disord. 2010;25:2604\u201312.","journal-title":"Mov Disord"},{"key":"159_CR17","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/BF02309628","volume":"8","author":"S Gilman","year":"1998","unstructured":"Gilman S, Low P, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy: American Autonomic Society and American Academy of Neurology. Clin Auton Res. 1998;8:359\u201362.","journal-title":"Clin Auton Res"},{"key":"159_CR18","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2165\/11537810-000000000-00000","volume":"24","author":"S Perez-Lloret","year":"2010","unstructured":"Perez-Lloret S, Rascol O. Dopamine receptor agonists for the treatment of early or advanced Parkinson\u2019s disease. CNS Drugs. 2010;24:941\u201368.","journal-title":"CNS Drugs"},{"key":"159_CR19","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/mds.22564","volume":"24","author":"MM Trujillo-Martin","year":"2009","unstructured":"Trujillo-Martin MM, Serrano-Aguilar P, Monton-Alvarez F, et al. Effectiveness and safety of treatments for degenerative ataxias: a systematic review. Mov Disord. 2009;24:1111\u201324.","journal-title":"Mov Disord"},{"key":"159_CR20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00415-009-5255-7","volume":"257","author":"C Colosimo","year":"2010","unstructured":"Colosimo C, Morgante L, Antonini A, et al. Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. J Neurol. 2010;257:5\u201314.","journal-title":"J Neurol"},{"key":"159_CR21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/nau.20461","volume":"27","author":"AG Papatsoris","year":"2008","unstructured":"Papatsoris AG, Papapetropoulos S, Singer C, et al. Urinary and erectile dysfunction in multiple system atrophy (MSA). Neurourol Urodyn. 2008;27:22\u20137.","journal-title":"Neurourol Urodyn"},{"key":"159_CR22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0165-1838(99)00105-8","volume":"79","author":"R Sakakibara","year":"2000","unstructured":"Sakakibara R, Hattori T, Uchiyama T, et al. Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte. J Auton Nerv Syst. 2000;79:191\u20135.","journal-title":"J Auton Nerv Syst"},{"key":"159_CR23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1756287213495100","volume":"5","author":"AP Cameron","year":"2013","unstructured":"Cameron AP, Jimbo M, Heidelbaugh JJ. Diagnosis and office-based treatment of urinary incontinence in adults: part two. Treatment. Ther Adv Urol. 2013;5:189\u2013200.","journal-title":"Ther Adv Urol"},{"key":"159_CR24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1474-4422(03)00662-8","volume":"3","author":"GK Wenning","year":"2004","unstructured":"Wenning GK, Colosimo C, Geser F, et al. Multiple system atrophy. Lancet Neurol. 2004;3:93\u2013103.","journal-title":"Lancet Neurol"},{"key":"159_CR25","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/mds.20891","volume":"21","author":"F Tison","year":"2006","unstructured":"Tison F, Yekhlef F, Chrysostome V. Depression and self-reported depressive symptoms in multiple system atrophy compared to Parkinson\u2019s disease. Mov Disord. 2006;21:1056\u20137.","journal-title":"Mov Disord"},{"key":"159_CR26","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/mds.23828","volume":"26","author":"E Bondon-Guitton","year":"2011","unstructured":"Bondon-Guitton E, Perez-Lloret S, Bagheri H, et al. Drug-induced parkinsonism: a review of 17\u00a0years\u2019 experience in a regional pharmacovigilance center in France. Mov Disord. 2011;26:2226\u201331.","journal-title":"Mov Disord"},{"key":"159_CR27","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.biopsych.2010.06.032","volume":"68","author":"CM Licht","year":"2010","unstructured":"Licht CM, de Geus EJ, van Dyck R, et al. Longitudinal evidence for unfavorable effects of antidepressants on heart rate variability. Biol Psychiatry. 2010;68:861\u20138.","journal-title":"Biol Psychiatry"},{"key":"159_CR28","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.2337\/dc11-1584","volume":"34","author":"E Cereda","year":"2011","unstructured":"Cereda E, Barichella M, Pedrolli C, et al. Diabetes and risk of Parkinson\u2019s disease: a systematic review and meta-analysis. Diabetes Care. 2011;34:2614\u201323.","journal-title":"Diabetes Care"},{"key":"159_CR29","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000078506","volume":"23","author":"V Chrysostome","year":"2004","unstructured":"Chrysostome V, Tison F, Yekhlef F, et al. Epidemiology of multiple system atrophy: a prevalence and pilot risk factor study in Aquitaine, France. Neuroepidemiology. 2004;23:201\u20138.","journal-title":"Neuroepidemiology"},{"key":"159_CR30","first-page":"123","volume":"7","author":"H Farzamnia","year":"2011","unstructured":"Farzamnia H, Rabiei K, Sadeghi M, et al. The predictive factors of recurrent deep vein thrombosis. ARYA Atheroscler. 2011;7:123\u20138.","journal-title":"ARYA Atheroscler"},{"key":"159_CR31","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/mds.22794","volume":"25","author":"A Schrag","year":"2010","unstructured":"Schrag A, Sheikh S, Quinn NP, et al. A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord. 2010;25:1077\u201381.","journal-title":"Mov Disord"},{"key":"159_CR32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1517\/14740338.2012.631910","volume":"11","author":"L Magro","year":"2012","unstructured":"Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions. Expert Opin Drug Saf. 2012;11:83\u201394.","journal-title":"Expert Opin Drug Saf"},{"key":"159_CR33","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/mds.22767","volume":"24","author":"C Schmidt","year":"2009","unstructured":"Schmidt C, Berg D, Prieur S, et al. Loss of nocturnal blood pressure fall in various extrapyramidal syndromes. Mov Disord. 2009;24:2136\u201342.","journal-title":"Mov Disord"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-014-0159-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-014-0159-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-014-0159-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:41:20Z","timestamp":1559490080000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-014-0159-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,29]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["159"],"URL":"https:\/\/doi.org\/10.1007\/s40263-014-0159-1","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,29]]}}}